Granted Patent B2

US 10,233,182 · App. 15/896,905 · Granted Mar 19, 2019

Inventors: Lee Babiss (Waltham, MA); Matthew Clark (Waltham, MA); Anthony D. Keefe (Waltham, MA); Mark J. Mulvihill (Waltham, MA); Haihong Ni (Beijing, CN); Louis Renzetti (Waltham, MA); Frank Ruebsam (Beijing, CN); Ce Wang (Beijing, CN); Zhifeng Xie (Beijing, CN); Ying Zhang (Waltham, MA)

Assignee: X-Rx, Inc.

C07D471/10A61K31/435A61K31/437A61K31/444A61K31/498A61K31/517A61K31/538A61K31/69A61K45/06C07D519/00C07F5/025

Abstract

Claims (81)

1. A compound according to Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

X 1 and X 2 are each independently selected from one or more of C 1-2 alkyl, C═O, NR 3 , or O;

X 3 is independently selected from one or more of C 1-2 alkyl, C═O, NR 3 , O, or CR 10 R 11 ;

m and n are each independently selected from 0, 1 or 2;

R 1 is aryl-C 3-12 heterocycloalkyl-, which is optionally substituted with one or more independent G 1 substituents;

R 2 is selected from C 0-12 alkyl-, C 3-12 cycloalkyl-C 0-12 alkyl-, C 3-12 heterocycloalkyl-C 0-12 alkyl-, heteroaryl-C 3-12 cycloalkyl-, or heteroaryl-C 3-12 heterocycloalkyl-, any of which is optionally substituted with one or more independent G 2 substituents;

R 2a is selected from C 0-12 alkyl-, C 3-12 cycloalkyl-C 0-12 alkyl-, C 3-12 heterocycloalkyl-C 0-12 alkylheteroaryl-C 3-12 cycloalkyl-, or heteroaryl-C 3-12 heterocycloalkyl-, any of which is optionally substituted with one or more independent G 2a substituents;

R 2 and R 2a are each independently a linear structure, or, R 2 and R 2a are taken together with the carbon atom to which they are attached to form a 3-12 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O) m1 ;

R 3 is selected from C 0-12 alkyl-, C 3-12 cycloalkyl-C 0-12 alkyl-, C 3-12 heterocycloalkyl-C 0-12 alkyl-, aryl-C 0-12 alkyl-, aryl-C 3-12 cycloalkyl-, aryl-C 3-12 heterocycloalkyl-, heteroaryl-C 0-12 alkyl-, heteroaryl-C 3-12 cycloalkyl-, or heteroaryl-C 3-12 heterocycloalkyl-, any of which is optionally substituted with one or more independent G 3 substituents;

R 4 is selected from C 0-12 alkyl-, C 3-12 cycloalkyl-C 0-12 alkyl-, C 3-12 heterocycloalkyl-C 0-12 alkyl-, aryl-C 0-12 alkyl-, aryl-C 3-12 cycloalkyl-, aryl-C 3-12 heterocycloalkyl-, heteroaryl-C 0-12 alkyl-, heteroaryl-C 3-12 cycloalkyl-, heteroaryl-C 3-12 heterocycloalkyl-, or pyridine-N-oxide, any of which is optionally substituted with one or more independent G 4 substituents;

G 1 , G 2 , G 2a , G 3 , and G 4 are each independently selected from one or more of H, D, halo, —CN, —CD 3 , —OCD 3 , -oxo-, —CF 3 , —OCF 3 , —OCHF 2 , —NR 5 R 6 , —NO 2 , —B(OH) 2 , —PO(OR 12 ) 2 , —PO(OR 12 )R 13 , —CONR 12 OH, —C 0-12 alkyl, —C 2-12 alkenyl, —C 2-12 alkynyl, C 3-12 cycloalkyl-C 0-12 alkyl-, C 3-12 heterocycloalkyl-C 0-12 alkyl-, aryl-C 0-12 alkyl-, heteroaryl-C 0-12 alkyl-, —OC 0-12 alkyl, —S(O) n1 R 12 , —C(O)R 12 , —C(O)NR 12 R 13 , —C(O)—C(O)NR 12 R 13 , —C(O)OR 12 , —C(O)—C(O)OR 12 , —OC(O)R 12 , —NR 12 C(O)R 13 , —NR 12 C(O)OR 13 , —NR 12 S(O) 2 R 13 , —(CR 14 R 15 )C(O)R 13 , —(CR 14 R 15 )C(O)OR 12 , —(CR 14 R 15 )C(O)NR 12 R 13 , —(CR 14 R 15 ) n1 S(O) 2 NR 12 R 13 , —(CR 14 R 15 ) n1 NR 12 R 13 , —(CR 14 R 15 ) n1 OR 12 , —(CR 14 R 15 ) n1 S(O) n2 R 12 , —NR 16 C(O)NR 12 R 13 , —NR 16 S(O) 2 NR 12 R 13 or —NR 16 S(O)NR 12 R 13 , any of which is optionally substituted with one or more independent Q 1 substituents;

Q 1 is selected from H, D, halo, —CN, —CD 3 , —OCD 3 , -oxo-, —CF 3 , —OCF 3 , —OCHF 2 , —NO 2 , —B(OH) 2 , —PO(OR 17 ) 2 , —PO(OR 17 )R 18 , NR 17 R 18 , —CONR 17 OH, C 0-12 alkyl-, —C 2-12 alkenyl, —C 2-12 alkynyl, aryl-C 0-12 alkyl-, heteroaryl-C 0-12 alkyl-, C 3-12 cycloalkyl-C 0-12 alkyl-, C 3-12 heterocycloalkyl-C 0-12 alkyl-, aryl-C 0-12 cycloalkyl-, heteroaryl-C 3-12 cycloalkyl-, C 3-12 heterocycloalkyl-C 3-12 cycloalkyl-, C 3-12 cycloalkyl-C 3-12 cycloalkyl-, C 1-12 alkyl-C 3-12 heterocycloalkyl-, C 3-12 heterocycloalkyl-C 3-12 heterocycloalkyl-, aryl-C 3-12 heterocycloalkyl-, heteroaryl-C 3-12 heterocycloalkyl-, —OC 0-12 alkyl, —C(O)—C(O)NR 17 R 18 , —C(O)—C(O)OR 17 , —OC(O)R 17 , —NR 17 C(O)R 18 , —NR 17 S(O) 2 R 18 , —(CR 19 R 20 ) n3 C(O)R 17 , —(CR 19 R 20 ) n3 C(O)OR 17 , —(CR 19 R 20 ) n3 C(O)NR 17 R 18 , —(CR 19 R 20 ) n3 S(O) 2 NR 17 R 18 , —(CR 19 R 20 ) n3 NR 17 R 18 , —(CR 19 R 20 ) n3 OR 17 , —(CR 19 R 20 ) n3 S(O) n4 R 17 , —NR 21 C(O)NR 17 R 18 , —NR 21 S(O) 2 NR 17 R 18 or —NR 21 S(O)NR 17 R 18 , any of which is optionally substituted with one or more independent Q 2 substituents;

Q 2 is selected from one or more of H, D, halo, —CN, -oxo-, —CD 3 , —OCD 3 , —CF 3 , —OCF 3 , —OCHF 2 , —NO 2 , —B(OH) 2 , —PO(OR 27 ) 2 , —PO(OR 27 )R 28 , —CONR 27 OH, —CONR 27 R 28 C 0-12 alkyl-, —C 2-12 alkenyl, —C 2-12 alkynyl, —OC 0-12 alkyl, aryl-C 0-12 alkyl-, heteroaryl-C 0-12 alkyl-, C 3-12 cycloalkyl-C 0-12 alkyl-, C 3-12 heterocycloalkyl-C 0-12 alkyl-, aryl-C 0-12 cycloalkyl-, heteroaryl-C 3-12 cycloalkyl-, C 3-12 heterocycloalkyl-C 3-12 cycloalkyl-, C 3-12 cycloalkyl-C 3-12 cycloalkyl-, C 1-12 alkyl-C 3-12 heterocycloalkyl-, C 3-12 heterocycloalkyl-C 3-12 heterocycloalkyl-, aryl-C 3-12 heterocycloalkyl-, heteroaryl-C 3-12 heterocycloalkyl-, —C(O)—C(O)NR 27 R 28 , —C 0-12 alkylC(O)OR 27 , —C(O)—C(O)OR 27 , —OC(O)R 27 , —NR 27 C(O)R 28 , —NR 27 C(O)OR 28 , —NR 27 S(O) 2 R 28 , —(CR 29 R 30 ) n5 C(O)R 27 , —(CR 29 R 30 ) n5 C(O)OR 27 , —(CR 29 R 30 ) n5 C(O)NR 27 R 28 , —(CR 29 R 30 ) n5 S(O) 2 NR 27 R 28 , —(CR 29 R 30 ) n5 NR 27 R 28 , —(CR 29 R 30 ) n5 OR 27 , —(CR 29 R 30 ) n5 S(O) n6 R 27 , —NR 30 C(O)NR 27 R 28 , —NR 30 S(O) 2 NR 27 R 28 or —NR 30 S(O)NR 27 R 28 substituents, any of which may be optionally substituted;

R 5 , R 6 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , and R 16 are each independently selected from one or more of H, C 1-6 alkyl-, C 3-8 cycloalkyl-C 0-6 alkyl-, C 3-8 heterocycloalkyl-C 0-6 alkyl-, aryl-C 0-6 alkyl-, aryl-C 3-8 cycloalkyl-, aryl-C 3-8 heterocycloalkyl-, heteroaryl-C 1-6 alkyl-, heteroaryl-C 3-8 cycloalkyl- or heteroaryl-C 3-8 heterocycloalkyl-, any of which may be optionally substituted;

R 17 , R 18 , R 19 , R 20 , R 21 , R 27 , R 28 , R 29 , and R 30 are each independently selected from H, C 1-6 alkyl-, C 3-8 cycloalkyl-C 0-6 alkyl-, C 3-8 heterocycloalkyl-C 0-6 alkyl-, aryl-C 0-6 alkyl-, aryl-C 3-8 cycloalkyl-, aryl-C 3-8 heterocycloalkyl-, heteroaryl-C 1-6 alkyl-, heteroaryl-C 3-8 cycloalkyl- or heteroaryl-C 3-8 heterocycloalkyl-, any of which may be optionally substituted;

—NR 5 R 6 and —NR 12 R 13 are each independently a linear structure, or, R 5 and R 6 , or R 12 and R 13 , respectively, are taken together with the nitrogen atom to which they are attached to form a 3-12 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O) m2 ;

—CR 10 R 11 and —CR 14 R 15 are each independently a linear structure, or, R 10 and R 11 , or R 14 and R 15 respectively, are taken together with the carbon atom to which they are attached to form a 3-12 membered saturated or unsaturated ring, wherein said ring optionally includes one or more heteroatoms selected from O, N, or S(O) m3 ;

—CR 19 R 20 is a linear structure, or, R 19 and R 20 are taken together with the carbon atom to which they are attached to form a 3-12 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O) m4 ;

—NR 17 R 18 is a linear structure, or, R 17 and R 18 are taken together with the nitrogen atom to which they are attached to form a 3-12 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O) m5 ;

—CR 29 R 30 is a linear structure, or, R 29 and R 30 are taken together with the carbon atom to which they are attached to form a 3-12 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O) m6 ;

—NR 27 R 28 is a linear structure, or, R 27 and R 28 are taken together with the nitrogen atom to which they are attached to form a 3-12 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O) m7 ;

wherein m1, m2, m3, m4, m5, m6, m7, n1, n2, n3, n4, n5 and n6 are each independently selected from 0, 1 or 2.

2. The compound or salt of claim 1 , wherein:

R 2 is selected from C 0-8 alkyl-, C 3-8 cycloalkyl-C 0-8 alkyl-, or C 3-8 heterocycloalkyl-C 0-8 alkyl-;

R 2a is C 0-8 alkyl-;

G 2 is selected from one or more of H, halo, —CN, —CD 3 , —OCD 3 , —CF 3 , —OCF 3 , —OCHF 2 , or —OC 0-8 alkyl;

R 2 and R 2a are each independently a linear structure, or, R 2 and R 2a are taken together with the carbon atom to which they are attached to form a 3-12 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, or N.

3. The compound or salt of claim 1 , wherein G 2 is selected from 0 to 3 of H, halo, —CN, —CD 3 , —OCD 3 , —CF 3 , —OCF 3 , —OCHF 2 , or —OC 0-8 alkyl.

4. The compound or salt of claim 1 , wherein:

R 3 is selected from C 0-8 alkyl-, C 3-8 cycloalkyl-C 0-8 alkyl-, or C 3-8 heterocycloalkyl-C 0-8 alkyl-;

G 3 is selected from one or more of H, D, halo, —CN, —CD 3 , —OCD 3 , -oxo-, —CF 3 , —OCF 3 , —OCHF 2 , —NR 5 R 6 , —C 0-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, —OC 0-8 alkyl, —S(O) n1 R 12 , —C(O)R 12 , —C(O)NR 12 R 13 , or —C(O)OR 12 .

5. The compound or salt of claim 1 , wherein G 3 is selected from 0 to 3 of H, D, halo, —CN, —CD 3 , —OCD 3 , -oxo-, —CF 3 , —OCF 3 , —OCHF 2 , —NR 5 R 6 , —C 0-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, —OC 0-8 alkyl, —S(O) n1 R 12 , —C(O)R 12 , —C(O)NR 12 R 13 , or —C(O)OR 12 .

6. The compound or salt of claim 1 , wherein:

R 4 is selected from C 0-8 alkyl-, C 3-8 cycloalkyl-C 3-8 alkyl-, C 3-8 heterocycloalkyl-C 0-8 alkyl-, aryl-C 0-8 alkyl-, heteroaryl-C 0-8 alkyl-, heteroaryl-C 3-8 cycloalkyl-, heteroaryl-C 3-8 heterocycloalkyl-, or pyridine-N-oxide;

G 4 is selected from one or more of H, D, halo, —CN, —CD 3 , —OCD 3 , -oxo-, —CF 3 , —OCF 3 , —OCHF 2 , —NR 5 R 6 , —NO 2 , —B(OH) 2 , —CONR 12 OH, —C 0-8 alkyl, C 3-8 cycloalkyl-C 0-8 alkyl-, C 3-8 heterocycloalkyl-C 0-8 alkyl-, aryl-C 0-8 alkyl-, heteroaryl-C 0-8 alkyl-, —OC 0-8 alkyl, —S(O) n1 R 12 , —C(O)R 12 , —C(O)NR 12 R 13 , —C(O)C(O)NR 12 R 13 , —C(O)OR 12 , —C(O)—C(O)OR 12 , —OC(O)R 12 , —NR 12 C(O)R 13 , —NR 12 C(O)OR 13 , —(CR 14 R 15 )C(O)R 13 , —(CR 14 R 15 ) n1 S(O) 2 NR 12 R 13 , —(CR 14 R 15 ) n1 NR 12 R 13 , —(CR 14 R 15 ) n1 OR 12 , —(CR 14 R 15 ) n1 S(O) n2 R 12 , or —NR 16 C(O)NR 12 R 13 .

7. The compound or salt of claim 1 , wherein G 4 is selected from 0 to 3 of H, D, halo, —CN, —CD 3 , —OCD 3 , -oxo-, —CF 3 , —OCF 3 , —OCHF 2 , —NR 5 R 6 , —NO 2 , —B(OH) 2 , —CONR 12 OH, —C 0-8 alkyl, C 3-8 cycloalkyl-C 0-8 alkyl-, C 3-8 heterocycloalkyl-C 0-8 alkyl-, aryl-C 0-8 alkyl-, heteroaryl-C 0-8 alkyl-, —OC 0-8 alkyl, —S(O) n1 OR 12 , —C(O)R 12 , —C(O)NR 12 R 13 , —C(O)—C(O)NR 12 R 13 , —C(O)OR 12 , —C(O)—C(O)OR 12 , —OC(O)R 12 , —NR 12 C(O)R 13 , —NR 12 C(O)OR 13 , —(CR 14 R 15 )C(O)R 13 , —(CR 14 R 15 ) n1 S(O) 2 NR 12 R 13 , —(CR 14 R 15 ) n1 NR 12 R 13 , —(CR 14 R 15 ) n1 OR 12 , —(CR 14 R 15 ) n1 S(O) n2 R 12 , or —NR 16 C(O)NR 12 R 13 .

8. The compound or salt of claim 1 , wherein:

Q 1 is selected from H, D, halo, —CN, —CD 3 , —OCD 3 , -oxo-, —CF 3 , —OCF 3 , —OCHF 2 , NR 17 R 18 , C 0-8 alkyl-, aryl-C 0-8 alkyl-, heteroaryl-C 0-8 alkyl-, C 3-8 cycloalkyl-C 0-8 alkyl-, C 3-8 heterocycloalkyl-C 0-8 alkyl-, aryl-C 0-8 cycloalkyl-, heteroaryl-C 3-8 cycloalkyl-, C 3-8 heterocycloalkyl-C 3-8 cycloalkyl-, C 3-8 cycloalkyl-C 3-8 cycloalkyl-, C 1-8 alkyl-C 3-8 heterocycloalkyl-, C 3-8 heterocycloalkyl-C 3-8 heterocycloalkyl-, aryl-C 3-8 heterocycloalkyl-, heteroaryl-C 3-8 heterocycloalkyl-, —OC 0-8 alkyl, —C(O)—C(O)NR 17 R 18 , —C(O)—C(O)OR 17 , —OC(O)R 17 , —NR 17 C(O)R 18 , —NR 17 S(O) 2 R 18 , —(CR 19 R 20 ) n3 C(O)R 17 , —(CR 19 R 20 ) n3 C(O)OR 17 , —(CR 19 R 20 ) n3 C(O)NR 17 R 18 , —(CR 19 R 20 ) n3 S(O) 2 NR 17 R 18 , —(CR 19 R 20 ) n3 NR 17 R 18 , —(CR 19 R 20 ) n3 OR 17 , —(CR 19 R 20 ) n3 S(O) n4 R 17 , —NR 21 C(O)NR 17 R 18 , —NR 21 S(O) 2 NR 17 R 18 , or —NR 21 S(O)NR 17 R 18 .

9. The compound or salt of claim 1 , wherein:

R 2 is selected from C 0-6 alkyl-, C 3-6 cycloalkyl-C 0-6 alkyl-, or C 3-6 heterocycloalkyl-C 0-6 alkyl-;

R 2a is C 0-6 alkyl-;

G 2 is selected from one or more of H, halo, —CN, —CD 3 , —OCD 3 , —CF 3 , —OCF 3 , —OCHF 2 , or —OC 0-6 alkyl;

R 2 and R 2a are each independently a linear structure, or, R 2 and R 2a are taken together with the carbon atom to which they are attached to form a 3-12 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, or N.

10. The compound or salt of claim 1 , wherein: R 2 and R 2a are each independently a linear structure, or, R 2 and R 2a are taken together with the carbon atom to which they are attached to form a 4-6 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, or N.

11. The compound or salt of claim 1 , wherein G 2 is selected from 0 to 2 of H, halo, —CN, —CD 3 , —OCD 3 , —CF 3 , —OCF 3 , —OCHF 2 , or —OC 0-6 alkyl.

12. The compound or salt of claim 1 , wherein:

R 3 is selected from C 0-6 alkyl-, C 3-6 cycloalkyl-C 0-6 alkyl-, or C 3-6 heterocycloalkyl-C 0-6 alkyl-;

G 3 is selected from one or more of H, D, halo, —CN, —CD 3 , —OCD 3 , -oxo-, —CF 3 , —OCF 3 , —OCHF 2 , —NR 5 R 6 , —C 0-6 alkyl, —C 2-6 alkenyl, —C 2-6 alkynyl, —OC 0-6 alkyl, —S(O) n1 R 12 , —C(O)R 12 , —C(O)NR 12 R 13 , or —C(O)OR 12 .

13. The compound or salt of claim 1 , wherein G 3 is selected from 0 to 2 of H, D, halo, —CN, —CD 3 , —OCD 3 , -oxo-, —CF 3 , —OCF 3 , —OCHF 2 , —NR 5 R 6 , —C 0-6 alkyl, —C 2-6 alkenyl, —C 2-6 alkynyl, —OC 0-6 alkyl, —S(O) n1 R 12 , —C(O)R 12 , —C(O)NR 12 R 13 , or —C(O)OR 12 .

14. The compound or salt of claim 1 , wherein:

R 4 is selected from C 0-6 alkyl-, C 3-6 cycloalkyl-C 0-6 alkyl-, C 3-6 heterocycloalkyl-C 0-6 alkyl-, aryl-C 0-6 alkyl-, heteroaryl-C 0-6 alkyl-, heteroaryl-C 3-6 cycloalkyl-, heteroaryl-C 3-6 heterocycloalkyl-, or pyridine-N-oxide;

G 4 is selected from one or more of H, D, halo, —CN, —CD 3 , —OCD 3 , -oxo-, —CF 3 , —OCF 3 , —OCHF 2 , —NR 5 R 6 , —NO 2 , —B(OH) 2 , —CONR 12 OH, —C 0-6 alkyl, C 3-6 cycloalkyl-C 0-6 alkyl-, C 3-6 heterocycloalkyl-C 0-6 alkyl-, aryl-C 0-6 alkyl-, heteroaryl-C 0-6 alkyl-, —OC 0-6 alkyl, —S(O) n1 R 12 , —C(O)R 12 , —C(O)NR 12 R 13 , —C(O)C(O)NR 12 R 13 , —C(O)OR 12 , —C(O)—C(O)OR 12 , —OC(O)R 12 , —NR 12 C(O)R 13 , —NR 12 C(O)OR 13 , —(CR 14 R 15 )C(O)R 13 , —(CR 14 R 15 ) n1 S(O) 2 NR 12 R 13 , —(CR 14 R 15 ) n1 NR 12 R 13 , —(CR 14 R 15 ) n1 OR 12 , —(CR 14 R 15 ) n1 S(O) n2 R 12 , or —NR 16 C(O)NR 12 R 13 .

15. The compound or salt of claim 1 , G 4 is selected from 0 to 2 of H, D, halo, —CN, —CD 3 , —OCD 3 , -oxo-, —CF 3 , —OCF 3 , —OCHF 2 , —NR 5 R 6 , —NO 2 , —B(OH) 2 , —CONR 12 OH, —C 0-6 alkyl, C 3-6 cycloalkyl-C 0-6 alkyl-, C 3-6 heterocycloalkyl-C 0-6 alkyl-, aryl-C 0-6 alkyl-, heteroaryl-C 0-6 alkyl-, —OC 0-6 alkyl, —S(O) n1 R 12 , —C(O)R 12 , —C(O)NR 12 R 13 , —C(O)—C(O)NR 12 R 13 , —C(O)OR 12 , —C(O)—C(O)OR 12 , —OC(O)R 12 , —NR 12 C(O)R 13 , —NR 12 C(O)OR 13 , —(CR 14 R 15 )C(O)R 13 , —(CR 14 R 15 ) n1 S(O) 2 NR 12 R 13 , —(CR 14 R 15 ) n1 NR 12 R 13 , —(CR 14 R 15 ) n1 OR 12 , —(CR 14 R 15 ) n1 S(O) n2 R 12 , or —NR 16 C(O)NR 12 R 13 .

16. The compound or salt of claim 1 , wherein:

Q 1 is selected from H, D, halo, —CN, —CD 3 , —OCD 3 , -oxo-, —CF 3 , —OCF 3 , —OCHF 2 , NR 17 R 18 , C 0-6 alkyl-, aryl-C 0-6 alkyl-, heteroaryl-C 0-6 alkyl-, C 3-6 cycloalkyl-C 0-6 alkyl-, C 3-6 heterocycloalkyl-C 0-6 alkyl-, aryl-C 0-6 cycloalkyl-, heteroaryl-C 3-6 cycloalkyl-, C 3-6 heterocycloalkyl-C 3-6 cycloalkyl-, C 3-6 cycloalkyl-C 3-6 cycloalkyl-, C 1-6 alkyl-C 3-6 heterocycloalkyl-, C 3-6 heterocycloalkyl-C 3-6 heterocycloalkyl-, aryl-C 3-6 heterocycloalkyl-, heteroaryl-C 3-6 heterocycloalkyl-, —OC 0-6 alkyl, —C(O)—C(O)NR 17 R 18 , —C(O)—C(O)OR 17 , —OC(O)R 17 , —NR 17 C(O)R 18 , —NR 17 S(O) 2 R 18 , —(CR 19 R 20 ) n3 C(O)R 17 , —(CR 19 R 20 ) n3 C(O)OR 17 , —(CR 19 R 20 ) n3 C(O)NR 17 R 18 , —(CR 19 R 20 ) n3 S(O) 2 NR 17 R 18 , —(CR 19 R 20 ) n3 NR 17 R 18 , —(CR 19 R 20 ) n3 OR 17 , —(CR 19 R 20 ) n3 S(O) n4 R 17 , —NR 21 C(O)NR 17 R 18 , —NR 21 S(O) 2 NR 17 R 18 , or —NR 21 S(O)NR 17 R 18 .

17. The compound or salt of claim 1 , wherein:

R 2 is selected from methyl, ethyl, propyl, isopropyl, or one of the following groups:

and R 2a is selected H, methyl, ethyl, propyl, isopropyl; or

R 2 and R 2a are taken together with the carbon atom to which they are attached to form one of the following groups:

18. The compound or salt of claim 1 , wherein:

—NR 5 R 6 and —NR 12 R 13 are each independently a linear structure, or, R 5 and R 6 , or R 12 and R 13 , respectively, are taken together with the nitrogen atom to which they are attached to form a 4-8 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O) m2 ;

—CR 10 R 11 and —CR 14 R 15 are each independently a linear structure, or, R 10 and R 11 , or R 14 and R 15 respectively, are taken together with the carbon atom to which they are attached to form a 4-8 membered saturated or unsaturated ring, wherein said ring optionally includes one or more heteroatoms selected from O, N, or S(O) m3 ;

—CR 19 R 20 is a linear structure, or, R 19 and R 20 are taken together with the carbon atom to which they are attached to form a 4-8 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O) m4 ;

—NR 17 R 18 is a linear structure, or, R 17 and R 18 are taken together with the nitrogen atom to which they are attached to form a 4-8 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O) m5 ;

—CR 29 R 30 is a linear structure, or, R 29 and R 30 are taken together with the carbon atom to which they are attached to form a 4-8 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O) m6 ;

—NR 27 R 28 is a linear structure, or, R 27 and R 28 are taken together with the nitrogen atom to which they are attached to form a 4-8 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O) m7 ;

wherein m2, m3, m4, m5, m6, and m7 are each independently selected from 0, 1 or 2.

19. The compound or salt of claim 1 , which is represented by the Formula Ia:

wherein X 3 is selected from C═O, or CRo 10 R 11 .

20. The compound of claim 19 , wherein R 2a is hydrogen.

21. The compound of claim 19 , wherein R 2 is C 1-12 alkyl-, C 3-12 cycloalkyl-, or C 1-12 heteroalkyl any of which is optionally substituted with one or more independent G 2 substituents.

22. The compound of claim 19 , wherein R 3 is C 1-12 alkyl or C 1-12 heteroalkyl.

23. The compound of claim 19 , wherein R 4 is C 1-12 alkyl, C 3-8 cycloalkyl, aryl, heteroaryl, aryl-C 1-6 alkyl, heteroaryl-C 1-6 alkyl, or C 3-12 heterocycloalkyl, any of which is optionally substituted with one or more independent Q 1 substituents.

24. The compound of claim 19 , wherein X 3 is C═O.

25. The compound of claim 19 , wherein X 3 is CR 10 R 11 wherein R 10 is hydrogen and R 11 is hydrogen or methyl.

26. The compound or salt of claim 1 , wherein the compounds of Formula I are inhibitors of ATX.

27. A pharmaceutical composition comprising the compound or salt of a compound according to claim 1 , formulated with or without one or more pharmaceutical carriers.

28. A method for inhibiting autotaxin (ATX) comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

29. The method of claim 28 , wherein the compounds binds to and inhibits ATX providing a reduction in LPA levels.

30. The method according to claim 28 comprising administering to the subject one or more additional therapeutically active agents selected from: corticosteroids, immunosuppressants, analgesics, anti-cancer agents, anti-inflammatories, non-steroidal anti-inflammatories, dual cyclooxygenase-1 and -2 inhibitors, cyclooxygenase-2 selective inhibitors, TNFα blockers, kinase inhibitors, chemokine receptor antagonists, bronchodilators, leukotriene receptor antagonists, leukotriene formation inhibitors, prostaglandin receptor antagonists, prostaglandin formation inhibitors, monoacylglycerol kinase inhibitors, phospholipase A1 inhibitors, phospholipase A2 inhibitors, lysophospholipase D (lysoPLD) inhibitors, autotaxin inhibitors, and LPA receptor antagonists.

Assignments (9)

Continuity (3)